Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat
December 21, 2018 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group Grants Exclusive Licensing Rights to Menarini for Pracinostat Licensing rights are worldwide excluding US, Canada, Japan and South America Lugano, Switzerland and Florence, Italy,...
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US
December 12, 2018 08:00 ET
|
Helsinn Healthcare S.A.
Helsinn Group Announces new Permanent J Code for AKYNZEO® (fosnetupitant and palonosetron) for injection in the US Akynzeo® for injection received a permanent J code, J1454, in the US, by the...
Helsinn and Lyfebulb Announce Partnership for Second Annual Patient-Driven Innovation Summit in Cancer
November 27, 2018 10:52 ET
|
Helsinn Healthcare S.A.
The award will be presented to the Patient Entrepreneur demonstrating outstanding science and potential to bring their idea to the market for cancer patients LUGANO, SWITZERLAND, AND NEW YORK, NY,...